Literature DB >> 2096159

Two cases of Graves' disease with antithyroid hormone antibodies: implication on the role of thyroglobulin as an antigen.

S Sakata1, K Nagai, O Tarutani, Y Kohno, K Saito, T Komaki, H Takuno, M Matsuda, T Ogawa, N Tokimitsu.   

Abstract

We have experienced two cases of Graves' disease with antithyroid hormone autoantibodies (Case 1: anti-T4; Case 2: anti-T3) who finally underwent subtotal thyroidectomy after antithyroid drug treatment. Using serial sera obtained before and after operation, the correlation between titers of antithyroglobulin (anti-Tg) and anti-T4 or anti-T3 autoantibodies was examined in each case. There was a significant positive correlation between titers of anti-T4 (Case 1, r = 0.90, p less than 0.05), or anti-T3 (Case 2, r = 0.64, p less than 0.01) and anti-Tg antibodies. Using the homogenate of the thyroid tissue, it was found that the sole iodoprotein in the thyroid gland in each patient was 660 KDa Tg. In addition, Tg purified from the thyroid gland from Case 2 showed different immunological activity with normal Tg in two out of four murine monoclonal anti-Tg antibodies tested. On the other hand, Tg from Case 1 had identical immunological activity with normal Tg in every four monoclonal antibodies. These results are consistent with the view that the antigen responsible for the development of antithyroid hormone autoantibodies is Tg, at least in our two cases. The reason for the persistence of anti-T3 autoantibodies in Case 2, despite the subtotal thyroidectomy, could be due to some unidentified structural abnormalities of Tg which was detected only by the monoclonal anti-Tg antibodies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2096159     DOI: 10.1007/BF03349632

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  ELECTROPHORETIC STUDIES OF THYROXINE AND TRIIODOTHYRONINE BINDING BY THE SERA OF GUINEA PIGS IMMUNIZED AGAINST THYROGLOBULIN.

Authors:  B N PREMACHANDRA; A K RAY; Y HIRATA; H T BLUMENTHAL
Journal:  Endocrinology       Date:  1963-08       Impact factor: 4.736

2.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

3.  On the role of thyroglobulin as an antigen of thyroid hormone autoantibodies.

Authors:  S Sakata
Journal:  Clin Chim Acta       Date:  1990-10-31       Impact factor: 3.786

4.  Immunological analysis of abnormal binding of thyroid hormone in the gamma globulin.

Authors:  Y Ochi; K Shiomi; T Hachiya; M Yoshimura; T Miyazaki
Journal:  J Clin Endocrinol Metab       Date:  1972-11       Impact factor: 5.958

5.  Spontaneous thyroiditis in the obese strain of chickens. VI. Thyroxine-binding antibodies.

Authors:  L A Nilsson; N R Rose; E Witebsky
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

6.  Primary structure of human thyroglobulin deduced from the sequence of its 8448-base complementary DNA.

Authors:  Y Malthiéry; S Lissitzky
Journal:  Eur J Biochem       Date:  1987-06-15

Review 7.  Autoantibodies against thyroid hormones or iodothyronine. Implications in diagnosis, thyroid function, treatment, and pathogenesis.

Authors:  S Sakata; S Nakamura; K Miura
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

8.  Production of anti-human thyroglobulin and anti-thyroid hormone antibodies in rabbits immunized with human thyroglobulin.

Authors:  S Sakata; S Nakamura; T Komaki; K Miura
Journal:  Endocrinol Jpn       Date:  1985-02

9.  Restricted antigenicity of thyroxyls in human thyroglobulin.

Authors:  P G Byfield; A Bond; S Copping; R L Himsworth
Journal:  Biochem J       Date:  1982-12-01       Impact factor: 3.857

10.  Autoantibodies to thyroglobulin cross reacting with iodothyronines.

Authors:  C J Pearce; P G Byfield; C J Edmonds; M R Lalloz; R L Himsworth
Journal:  Clin Endocrinol (Oxf)       Date:  1981-07       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.